NDASUBCUTANEOUSINJECTABLEPriority Review
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
APOKYN (apomorphine hydrochloride) by Sumitomo Dainippon Pharma is non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine d 4 receptor, and moderate affinity for the dopamine d 2 , d 3 , and d 5 , and adrenergic α 1 d, α 2 b, α 2 c receptors. Approved for parkinson's disease. First approved in 2004.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APOKYN (apomorphine hydrochloride) is a non-ergoline dopamine agonist administered via subcutaneous injection for acute, intermittent treatment of hypomobility episodes in Parkinson's disease patients. It works by stimulating post-synaptic dopamine D2-type receptors in the brain, with additional binding affinity for D3, D4, D5, and adrenergic receptors. The drug is used as rescue therapy for motor fluctuations in advanced Parkinson's disease.
$72MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest spending signals declining brand investment and potential team restructuring.
Mechanism of Action
non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D 4 receptor, and moderate affinity for the dopamine D 2 , D 3 , and D 5 , and adrenergic α 1 D, α 2 B, α 2 C receptors. The precise mechanism of action of APOKYN as a treatment for Parkinson's disease is unknown,…
Indications (1)
Clinical Trials (3)
Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®
Started Jan 2016
13 enrolled
Parkinson's DiseaseMotor Symptoms
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
Started Dec 2012
127 enrolled
Parkinson's DiseaseMotor SymptomsAkinesia+2 more
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
Started May 2007
117 enrolled
Parkinson's Disease
Worked on APOKYN at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.